Management of Moderate POstoperative Recurrence in Crohn's Disease: a randoMizEd contROLled Trial of Therapeutic Escalation, the POMEROL Trial. (POMEROL)
Latest Information Update: 15 Jul 2024
At a glance
- Drugs Infliximab (Primary) ; Infliximab (Primary) ; Methotrexate; Tisopurine
- Indications Crohn's disease
- Focus Therapeutic Use
- Acronyms POMEROL
- 02 Aug 2022 Planned End Date changed from 15 Mar 2024 to 15 Jun 2024.
- 02 Aug 2022 Planned primary completion date changed from 30 Mar 2023 to 30 Jun 2023.
- 04 Jan 2022 New source identified and integrated (European Clinical Trials Database: EudraCT2021-002369-17).